Industry News
Phase 1 of Admedus HSV-2 trial achieves primary endpoint
Admedus (ASX:AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2). [ + ]
Seminal fluid shapes health of offspring
Researchers from the University of Adelaide's Robinson Institute have discovered that a man's seminal fluid plays a major role in various developmental stages of his offspring, including future health conditions. Their research has been published in Proceedings of the National Academy of Sciences. [ + ]
Seeing like a satellite
The eyes of mantis shrimp have a unique, previously undocumented colour vision system that uses 12 different types of photoreceptors. [ + ]
Mesoblast's MPCs reduce back pain in phase II trial
Patients with low back pain from early disc degeneration treated with Mesoblast (ASX:MSB) MPCs during a phase II trial reported reduced back pain and required fewer pain drugs compared to controls. [ + ]
Medtech event of the year open for registration
The annual AusMedtech national conference will again be held in Melbourne, from 1-2 April at the Hilton on the Park. The flagship medical technology event of the year has just confirmed Mick Farrell, CEO of ResMed, to speak on day one. [ + ]
Access to medical isotopes
Australian researchers and clinicians can now access locally produced medical isotopes thanks to a new collaborative arrangement. [ + ]
Drawbridge wins patents for anaesthesia candidate
Drawbridge Pharmaceuticals has picked up patents in six countries for Phaxan, its anaesthesia drug candidate that entered the phase IC trial stage this month. [ + ]
Viralytics to raise up to $27m for cancer trials
Viralytics (ASX:VLA) has launched a capital raising to secure funds for clinical trials of cancer treatment candidate Cavatak in melanoma and other solid tumours. [ + ]
Spinning cloth disc reactor accelerates enzyme reactions
Researchers from the University of Bath have developed a new enzymatic process intensification technology - the 'spinning cloth disc reactor' (SCDR) - which is one of only a few technologies available for accelerating the rate of an enzyme reaction. [ + ]
Qiagen submits C. difficile assay to FDA
Qiagen plans to roll out a portfolio of assays for the QIAsymphony platform to aid in the diagnosis of healthcare-associated infections (HAIs). The company's first new test, the artus C. difficile QS-RGQ MDx Kit, has been submitted to the US Food and Drug Administration (FDA). [ + ]
Burnet Institute to roll out cheap point-of-care HIV test
Burnet Institute has received US$1.6 million from UNITAID to begin evaluation studies of HIV test VISITECT CD4 in India and South Africa. The point-of-care test uses a small amount of blood from a finger prick to determine when an HIV-positive patient should start lifesaving treatment. Results of the test are available after 40 min at a cost of approximately $5. [ + ]
Nanoparticles provide a new way to treat heart attack
Researchers are recruiting nanobiology to change the way heart attacks are treated. [ + ]
Modelling ovarian cancer
Scientists at Queensland University of Technology (QUT), funded by Cancer Council Queensland, are conducting research into the deadliest form of ovarian cancer. [ + ]
Calzada scores licence deal for AOD9604
Calzada (ASX:CZD) subsidiary Metabolic has secured the first of what it hopes will be a number of licensing agreements with Australian compounding pharmacies for its peptide drug AOD9604. [ + ]
IDT Australia weighing acquiring HRT product
IDT Australia (ASX:IDT) is evaluating acquiring Perrigo's US ANDA filing for a synthetic oestrogen product, as it seeks to expand its specialty generic drug portfolio. [ + ]
